Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


Ongoing Clinical Trials in Second-Line HCC

September 8th 2017

Second-Line HCC: Unmet Needs

September 8th 2017

HCC: Evolution of Frontline Treatment

September 8th 2017

Frontline Lenvatinib in HCC: Study 304

September 8th 2017

Unmet Needs in Systemic Therapy for Liver Cancer

September 8th 2017

Initial Treatment Decisions in Liver Cancer

September 8th 2017

Evidence With SIRT in HCC

September 8th 2017

Role of TACE in Liver Cancer

September 8th 2017

Radiofrequency Ablation Vs Resection in HCC

September 8th 2017

HCC and Liver Transplantation

September 8th 2017

Liver Cancer Screening Strategies

September 8th 2017

Comorbidities and Management of HCC

September 8th 2017

Importance of Multidisciplinary Care in Liver Cancer

September 8th 2017

FDA Halts Enrollment on 3 Nivolumab Myeloma Trials

September 7th 2017

The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.

Proposed Changes to 340B May Curb Hospital Abuses

September 2nd 2017

Outpatient branded drug sales in the 340B Drug Pricing Program now amount to almost 8% of the total market, well up from 5.4% in 2012.

Novartis Sets a Price of $475,000 for CAR T-Cell Therapy

August 31st 2017

Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists.

The Value of MRD Testing in Lymphoid Malignancies

August 29th 2017

MRD Negativity in Multiple Myeloma

August 29th 2017

Reliability of MRD Testing: Sensitivity/Specificity

August 29th 2017

Varying Pertinence: MRD Testing Across Lymphomas

August 29th 2017